Health Care · Pharmaceutical Preparations

TRDA Entrada Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 168937574 filings
Russell 2000

TRDA at a glance

Entrada Therapeutics, Inc. (TRDA, SEC CIK 1689375) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Entrada Therapeutics, Inc. (TRDA) reported revenue of $25.4 million (down 87.9% from FY2024) and a net loss of $143.8 million. Diluted EPS was -$3.47.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Entrada Therapeutics, Inc. (TRDA) shares worth $71.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by MPM BioVentures 2014, L.P. on September 9, 2026 of 28,837 shares at $7.13 per share.
  • In the last 90 days, TRDA insiders reported 0 open-market purchases ($0) and 24 open-market sales ($7.2M) on Form 4, a net sale of $7.2M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$25.4M
−87.9% vs prior year
Insiders · 90 days
0 buys · 24 sells
Net −$7.2M
13F holders
24 funds
$71.8M · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Collaboration revenue $0.9M, down $0.7M YoY from $1.6M
  • Net loss $39.7M vs $44.1M YoY, operating loss $41.7M vs $47.1M
  • ENTR-601-44 highest program spend at $6.2M, ENTR-601-45 increased to $4.5M
  • Operating cash use $104.1M, marketable-securities maturities drove $124.9M investing inflow
  • Cash, equivalents and securities $193.0M, funding expected into fourth quarter 2027; additional funding required

Risk Factors

  • Newly added regulatory risk: October 2026 FDA orphan-drug designation for ENTR-601-45 may not deliver exclusivity or other benefits
  • Most material regulatory update: June 2026 FDA draft guidance permits one pivotal trial with confirmatory evidence, but additional trials remain possible
  • Compliance risk: BIOSECURE Act Section 851 could disrupt China-based suppliers and foreign contract manufacturers
  • Operational risk: Vertex controls VX-670 development, with interim GALILEO Phase 1/2 results expected in second half of 2026
  • Financial risk: Cash, equivalents and marketable securities fund operations into fourth quarter 2027, but substantial going-concern doubt remains

AI summary of the TRDA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Corporate updates included alongside quarterly results

Item EX-99.1: Item EX-99.1

  • Q3 2026 results show net loss $39.7M, or $0.94 per share, versus $44.1M, or $1.06, in Q3 2025
  • Cash, equivalents and marketable securities fell to $193.0M from $295.7M, supporting operations into Q4 2027
Filed Oct 14, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Positive first-cohort results for ENTR-601-45 in Phase 1/2 ELEVATE-45-201 study
  • Clinical program targets Duchenne muscular dystrophy, a key development milestone for Entrada

Item 8.01: Other Events

  • Cohort 1 showed dystrophin increase of 0.10% versus placebo decline of 0.02%, supporting biological activity at 5 mg/kg
  • Exon skipping rose 0.15% versus placebo decline of 0.04%, strengthening ENTR-601-45’s mechanistic evidence
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 announced August 5, 2026
  • Financial details and corporate updates contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q2 2026 net loss $42.8M, or $1.01 per share, versus $43.1M and $1.04 in Q2 2025
  • Cash, equivalents and marketable securities $223.0M, down from $295.7M, funding operations into Q3 2027

AI summaries of TRDA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TRDA

Don't miss the next TRDA filing

  • Alerts as it files. A push when TRDA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TRDA, by share count.
  • Ask anything. An AI agent that reads every TRDA filing and answers with sources.

TRDA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
MPM BioVentures 2014, L.P.SellSep 9, 2026$7.13
MPM BIOVENTURES 2018, L.P.SellSep 9, 2026$7.13
MPM BioVentures 2014, L.P.SellSep 8, 2026$7.41
MPM BIOVENTURES 2018, L.P.SellSep 8, 2026$7.41
MPM BIOVENTURES 2018, L.P.SellSep 4, 2026$7.11
MPM BioVentures 2014, L.P.SellSep 4, 2026$7.11
MPM BioVentures 2014, L.P.SellSep 3, 2026$7.17
MPM BIOVENTURES 2018, L.P.SellSep 3, 2026$7.17

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$129.0M$210.8M$25.4M
Operating Income-$3.2M$47.0M-$157.9M
Net Income-$6.7M$65.6M-$143.8M
Op. Margin-2.5%22.3%-621.1%
Net Margin-5.2%31.1%-565.5%
Balance Sheet
Total Assets-$526.3M$377.4M
Equity-$428.7M$306.1M
ROE-15.3%-47.0%
Per Share
EPS-$1.68$-3.47
Cash Flow
Operating CF$139.8M-$41.6M-$128.5M
CapEx-$3.2M$1.0M

Source: XBRL data in Entrada Therapeutics, Inc. (TRDA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TRDA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TRDA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$71.8M
Q2 202625$80.8M
Q1 202626$91.7M
Q4 202523$73.6M
Q3 202523$48.3M
Q2 202522$61.3M
Q1 202520$43.1M
Q4 202417$76.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TRDA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
8-KOct 14, 2026Analysis-
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Aug 31, 2026--
4Aug 31, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
4Aug 10, 2026--
4Aug 10, 2026--
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
4Aug 3, 2026--
4Aug 3, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--

Related Health Care companies

All Health Care →

TRDA SEC filings: frequently asked questions

Are TRDA insiders buying or selling?

In the last 90 days, Entrada Therapeutics, Inc. (TRDA) officers, directors and 10% owners reported no open-market purchases and 24 open-market sales worth $7.2 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TRDA stock?

As of September 30, 2026, the largest Entrada Therapeutics, Inc. (TRDA) holders among the 13F filers tracked by SignalX were BlackRock ($20.6 million), Merck & Co. ($11.0 million), Vanguard Capital Management LLC ($8.1 million), AQR Capital Management ($4.0 million), State Street Corp ($3.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TRDA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Entrada Therapeutics, Inc. (TRDA) reported revenue of $25.4 million (down 87.9% from FY2024) and a net loss of $143.8 million. Diluted EPS was -$3.47. The figures come from the XBRL data in the 10-K.

What did TRDA report in its latest 8-K?

Entrada Therapeutics, Inc. (TRDA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest TRDA SEC filings?

Entrada Therapeutics, Inc. (TRDA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on September 9, 2026.

What is TRDA's SEC CIK number?

Entrada Therapeutics, Inc. (TRDA)'s SEC Central Index Key (CIK) is 1689375. EDGAR lists every TRDA filing under that number.

Ask anything about TRDA

The research agent reads TRDA's filings, financials, insider trades and 13F holders, then answers with sources.